Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Mar;40(3):588–594. doi: 10.1128/aac.40.3.588

Susceptibilities of Candida spp. to antifungal agents visualized by two-dimensional scatterplots of relative growth.

F C Odds 1, G Dams 1, G Just 1, P Lewi 1
PMCID: PMC163163  PMID: 8851576

Abstract

The growth of 811 clinical yeast isolates in the presence of single concentrations of antifungal agents was measured spectrophotometrically and expressed as a percentage of growth in inhibitor-free control cultures. Two-dimensional scatterplots of the relative growth data allowed for the simple visual determination of some susceptibility trends, including correlations in relative growth between different agents and in relative susceptibilities between different yeast species. A positive susceptibility correlation was found for relative growth results with the azole antifungal agents fluconazole, itraconazole, and ketoconazole for 504 Candida albicans isolates. The relative growth scatterplots for fluconazole versus itraconazole showed that 50 (9.9%) of 504 C. albicans isolates were outliers with respect to the 95% confidence limits for a line of correlated relative growth established with an initial test panel of 59 isolates of this species. The outlying isolates were relatively less susceptible to fluconazole than to itraconazole under the conditions of the test. Most of the outliers were received in 1993 and 1994; only 3.9% of the isolates received in 1991 and 1992 and 1.7% of the isolates received before 1991 showed this differential susceptibility. In addition, most of the outliers came from patients with human immunodeficiency virus infections. The relative growth scatterplots confirmed the known high susceptibility of most Candida parapsilosis isolates to both fluconazole and itraconazole and the specifically low susceptibility of Candida krusei isolates to fluconazole. The scatterplots also illustrated a tendency towards lower (and correlative) relative growth among oral isolates obtained from AIDS patients who responded to azole antifungal treatment than among isolates from clinical nonresponders.

Full Text

The Full Text of this article is available as a PDF (264.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S43–S53. doi: 10.1093/clinids/14.supplement_1.s43. [DOI] [PubMed] [Google Scholar]
  2. Barchiesi F., Colombo A. L., McGough D. A., Fothergill A. W., Rinaldi M. G. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994 Jul;38(7):1530–1533. doi: 10.1128/aac.38.7.1530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cameron M. L., Schell W. A., Bruch S., Bartlett J. A., Waskin H. A., Perfect J. R. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Nov;37(11):2449–2453. doi: 10.1128/aac.37.11.2449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chavanet P., Lopez J., Grappin M., Bonnin A., Duong M., Waldner A., Buisson M., Camerlynck P., Portier H. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS. 1994 Jul;8(7):945–950. doi: 10.1097/00002030-199407000-00011. [DOI] [PubMed] [Google Scholar]
  5. Espinel-Ingroff A. Etest for antifungal susceptibility testing of yeasts. Diagn Microbiol Infect Dis. 1994 Aug;19(4):217–220. doi: 10.1016/0732-8893(94)90034-5. [DOI] [PubMed] [Google Scholar]
  6. Johnson E. M., Richardson M. D., Warnock D. W. In-vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother. 1984 Jun;13(6):547–558. doi: 10.1093/jac/13.6.547. [DOI] [PubMed] [Google Scholar]
  7. Odds F. C. Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents. Antimicrob Agents Chemother. 1992 Aug;36(8):1727–1737. doi: 10.1128/aac.36.8.1727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Odds F. C. Effects of temperature on anti-Candida activities of antifungal antibiotics. Antimicrob Agents Chemother. 1993 Apr;37(4):685–691. doi: 10.1128/aac.37.4.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Odds F. C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother. 1993 Apr;31(4):463–471. doi: 10.1093/jac/31.4.463. [DOI] [PubMed] [Google Scholar]
  10. Odds F. C., Vranckx L., Woestenborghs F. Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother. 1995 Sep;39(9):2051–2060. doi: 10.1128/aac.39.9.2051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pfaller M. A., Barry A. L. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol. 1994 Aug;32(8):1992–1996. doi: 10.1128/jcm.32.8.1992-1996.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Philpot C. M., Charles D. Determination of sensitivity to antifungal drugs: evaluation of an API kit. Br J Biomed Sci. 1993 Mar;50(1):27–30. [PubMed] [Google Scholar]
  13. Philpott-Howard J. N., Wade J. J., Mufti G. J., Brammer K. W., Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother. 1993 Jun;31(6):973–984. doi: 10.1093/jac/31.6.973. [DOI] [PubMed] [Google Scholar]
  14. Price M. F., LaRocco M. T., Gentry L. O. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994 Jun;38(6):1422–1424. doi: 10.1128/aac.38.6.1422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Quindós G., Salesa R., Carrillo-Muñoz A. J., Lipperheide V., Jáudenes L., San Millán R., Torres-Rodríguez J. M., Pontón J. Multicenter evaluation of ATB fungus: a standardized micromethod for yeast susceptibility testing. Chemotherapy. 1994 Jul-Aug;40(4):245–251. doi: 10.1159/000239200. [DOI] [PubMed] [Google Scholar]
  16. Rex J. H., Pfaller M. A., Rinaldi M. G., Polak A., Galgiani J. N. Antifungal susceptibility testing. Clin Microbiol Rev. 1993 Oct;6(4):367–381. doi: 10.1128/cmr.6.4.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rex J. H., Rinaldi M. G., Pfaller M. A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995 Jan;39(1):1–8. doi: 10.1128/aac.39.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ruhnke M., Eigler A., Tennagen I., Geiseler B., Engelmann E., Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol. 1994 Sep;32(9):2092–2098. doi: 10.1128/jcm.32.9.2092-2098.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ryley J. F., Wilson R. G., Barrett-Bee K. J. Azole resistance in Candida albicans. Sabouraudia. 1984;22(1):53–63. [PubMed] [Google Scholar]
  20. Sandven P., Bjørneklett A., Maeland A. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group. Antimicrob Agents Chemother. 1993 Nov;37(11):2443–2448. doi: 10.1128/aac.37.11.2443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Soll D. R. High-frequency switching in Candida albicans. Clin Microbiol Rev. 1992 Apr;5(2):183–203. doi: 10.1128/cmr.5.2.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Troillet N., Durussel C., Bille J., Glauser M. P., Chave J. P. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993 Dec;12(12):911–915. doi: 10.1007/BF01992164. [DOI] [PubMed] [Google Scholar]
  23. Vanden Bossche H., Marichal P., Odds F. C. Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 1994 Oct;2(10):393–400. doi: 10.1016/0966-842x(94)90618-1. [DOI] [PubMed] [Google Scholar]
  24. Warnock D. W. Azole drug resistance in Candida species. J Med Microbiol. 1992 Oct;37(4):225–226. doi: 10.1099/00222615-37-4-225. [DOI] [PubMed] [Google Scholar]
  25. Weber D. J., Rutala W. A., Samsa G. P., Wilson M. B., Hoffmann K. K. Relative frequency of nosocomial pathogens at a university hospital during the decade 1980 to 1989. Am J Infect Control. 1992 Aug;20(4):192–197. doi: 10.1016/s0196-6553(05)80145-2. [DOI] [PubMed] [Google Scholar]
  26. de Montclos M., de Montclos H., Flandrois J. P. Etude comparative de deux systèmes de détermination de la sensibilité des levures à quatre antifongiques. Pathol Biol (Paris) 1992 May;40(5):495–499. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES